STOCK TITAN

Xenon Pharmaceuticals Inc - XENE STOCK NEWS

Welcome to our dedicated news page for Xenon Pharmaceuticals (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xenon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xenon Pharmaceuticals's position in the market.

Rhea-AI Summary
Xenon Pharmaceuticals presents XEN1101 clinical data at the American Academy of Neurology 2024 Annual Meeting, showcasing positive results in epilepsy treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference on April 16-17, 2024. Ian Mortimer, President and CEO, will be the presenter. The webcast will be available on the company's website for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) will be presenting at the 23rd Annual Needham Healthcare Conference on April 11, 2024. The presentation will feature Ian Mortimer, President, and CEO, and Sherry Aulin, CFO. The webcast will be available on Xenon's website for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) will present at the Stifel 2024 Virtual CNS Days event with key executives discussing the company's future. The presentation will be live-streamed on their website for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
conferences
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) to present at Leerink Partners Global Biopharma Conference 2024 in Miami. Company executives to discuss future plans and strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
conferences
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. reports strong financial position with $930 million to support Phase 3 programs in epilepsy and major depressive disorder. Completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025. Conference call scheduled for today at 4:30 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) will release its Q4 and full year 2023 financial results on February 29, 2024, after the U.S. financial markets close. A conference call/webcast will follow at 4:30 pm Eastern Time. Investors can access the live webcast on Xenon's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) outlines progress within its pipeline programs and key milestones for 2024. The company anticipates completing patient enrollment in the XEN1101 Phase 3 X-TOLE2 clinical trial for focal onset seizures in the second half of 2024 and plans to initiate the XEN1101 Phase 3 program for major depressive disorder in 2024. The company also highlighted the positive data generated in the Phase 2 proof-of-concept X-NOVA clinical trial for depression and the ongoing progress in the Phase 3 epilepsy clinical trials. Additionally, Xenon is actively planning for late-stage development of XEN1101 in depression and evaluating potential development in additional neurological indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.23%
Tags
none
-
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (XENE) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Ian Mortimer, President and CEO, to present on January 8, 2024. Live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
conferences
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) closed its underwritten public offering of 9,846,157 common shares, generating approximately $345.0 million in gross proceeds. The offering included 1,384,615 shares from the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The public offering price was $32.50 per common share, and the pre-funded warrants were offered at a price of $32.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets acted as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
Xenon Pharmaceuticals Inc

Nasdaq:XENE

XENE Rankings

XENE Stock Data

3.12B
69.56M
0.38%
99.99%
3.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Burnaby

About XENE

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.